Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort

The oncologist

article

Jason M. Heckert¹  Daniel A. Pryma²  David A. Mankoff²  David C. Metz³  Bryson W. Katona³  Sarit T. Kipnis¹  Shria Kumar³  Samuel Botterbusch³  Alice Alderson³  Bonita Bennett³  Caroline Creamer³  Jennifer R. Eads⁴  Michael C. Soulen² 

[1] Division of Internal Medicine, Hospital of the University of Pennsylvania;Department of Radiology, Perelman School of Medicine, University of Pennsylvania;Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania;Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania

关键词: Peptide receptor radionuclide therapy;    Neuroendocrine tumor;    DOTATATE;    Lu-177;   

DOI  :  10.1634/theoncologist.2019-0743

学科分类：地质学

来源: AlphaMed Press Incorporated

【 摘 要 】

Background Peptide receptor radionuclide therapy (PRRT) is effective for treating midgut neuroendocrine tumors (NETs); however, incorporation of PRRT into routine practice in the U.S. is not well studied. Herein we analyze the first year of PRRT implementation to determine tolerance of PRRT and factors that increase risk of PRRT discontinuation. Materials and Methods Medical records were reviewed and data were abstracted on all patients with NETs scheduled for PRRT during the first year of PRRT implementation at a U.S. NET referral center (August 2018 through July 2019). Logistic regression was used to identify factors associated with PRRT discontinuation. Results Fifty-five patients (56% male) were scheduled for PRRT over the study period. The most common primary NET location was small bowel (47%), followed by pancreas (26%), and 84% of the NETs were World Health Organization grade 1 or 2. The cohort was heavily pretreated with somatostatin analog (SSA) therapy (98%), non-SSA systemic therapy (64%), primary tumor resection (73%), and liver-directed therapy (55%). At the time of analysis, 52 patients completed at least one PRRT treatment. Toxicities including bone marrow suppression and liver function test (LFT) abnormalities were comparable to prior publications. Eleven patients (21%) prematurely discontinued PRRT because of toxicity or an adverse event. Pretreatment LFT abnormality was associated with increased risk of PRRT cancellation (odds ratio: 12; 95% confidence interval: 2.59–55.54; p < .001). Conclusion PRRT can be administered to a diverse NET population at a U.S. NET referral center. Baseline liver function test abnormality increases the likelihood of PRRT discontinuation. Implications for Practice Peptide receptor radionuclide therapy (PRRT) can be successfully implemented at a U.S. neuroendocrine tumor (NET) referral center in a NET population that is diverse in tumor location, grade, and prior treatment history. Toxicity and adverse effects of PRRT are comparable to prior reports; however, 21% of individuals prematurely discontinued PRRT. Patients with baseline liver function test abnormalities were more likely to discontinue PRRT than patients with normal liver function tests, which should be taken into consideration when selecting treatment options for NETs.

【 授权许可】

CC BY|CC BY-NC